By integrating foundation models into its R&D pipeline, AstraZeneca seeks to enable data-driven discovery methods.

AstraZeneca is in advanced talks with Summit Therapeutics over a potential $15 billion deal for the lung cancer drug ...

Just days after President Donald Trump was elected in November, AstraZeneca unvei | AstraZeneca CEO Pascal Soriot is plotting ...

AstraZeneca is reportedly considering moving its listing to the US. Here's why AZN's expected departure is alarming for the ...

Datroway is used to treat an advanced form of non-small cell lung cancer in adults who had received prior treatment.

The company's exit from the U.K. market would spark a major index re-weighting, given AstraZeneca is the most valuable ...

The company's exit from the U.K. market would spark a major index re-weighting, given AstraZeneca is the most valuable ...

AstraZeneca CEO discusses leaving London for US and Japan facing new, bigger tariff - Stock markets updates and business news ...

London's blue-chip stock index edged higher and the midcap index fell on Wednesday as investors assessed a mixed bag of corporate news, including a media report that AstraZeneca is moving its listing ...

American Depositary Shares (ADSes) was lively on Tuesday, on news that its leadership intends to directly list its sock on a ...

Citing multiple sources, the Times said AstraZeneca CEO Pascal Soriot has spoken privately of his preference to move the FTSE 100 company's listing on a number of occasions and has even discussed ...